Zhejiang Doer Biologics

Privately held: no public share price · China

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 3
GLP-1R; GCGR; FGF21RProtein / enzyme therapeutic
ObesitySevere Hypertriglyceridemia

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
April 2028 (1)
DR10624Phase 2Hypertriglyceridemia
Est. primary completion 2028-04 · NCT07848880 · CT.gov ↗
What to watch
2029 (1)
February 2029 (1)
DR10624Phase 3Severe Hypertriglyceridemia (sHTG), Hypertriglyceridemia
Est. primary completion 2029-02-14 · NCT07693777 · CT.gov ↗
What to watch
2030 (1)
June 2030 (1)
DR10624Phase 3Severe Hypertriglyceridemia
Est. primary completion 2030-06 · NCT07680829 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (5)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$139M$631M$15.7B$872Mreport ↗
View 4 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1$203M$548M$18.3B$340Mreport ↗
2025-Q3$1.4B$605M$19.6B—report ↗
2025-Q2$139M$568M$20.0B$872Mreport ↗
2025-Q1$203M$548M$18.3B$340Mreport ↗